Advertisement

Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

  • Laura Amanda Vallejo-AparicioEmail author
  • Jesús Molina
  • Iñigo Ojanguren
  • Ana Viejo Casas
  • Alicia Huerta
  • Henrik Svedsater
Correction

Correction to: The European Journal of Health Economics  https://doi.org/10.1007/s10198-019-01101-x

In the published article, the Table 1 was published incorrectly.

The correct Table 1 is given below

Variables

FF/VI

184/22 mcg and 92/22 mcg

UC group

Monthly drug costs [17, 21]

€51.52a

ICS = €18.75b

ICS/LABA = €48.25b

Annual drug costs (€, 2018)

€627.26

€557.31

Asthma management direct annual costs (€, 2018)c [19, 20]

 Uncontrolled (ACT score ≤ 15)

€1919.01

 Partially controlled (ACT score 16–19)

€1015.61

 Well-controlled (ACT score ≥ 20)

€656.90

 Assumed proportion of days covered,  %

100

100

 Assumed current uptake,  %

10

90

 Assumed new uptake,  %

20

80

Percentage of subjects in each ACT category (ITT population, n = 4233) [18]

 Baseline

  Uncontrolled

41%

41%

  Partially controlled

31%

31%

  Well-controlled

28%

28%

 24 weeks

  Uncontrolled

20%

29%

  Partially controlled

20%

25%

  Well-controlled

60%

46%

 52 weeks

  Uncontrolled

21%

30%

  Partially controlled

20%

26%

  Well-controlled

59%

44%

FF/VI fluticasone furoate/vilanterol, ICS inhaled corticosteroid, ICS/LABA inhaled corticosteroid/long-acting beta-agonist, ACT Asthma Control Test, ITT intention-to-treat

aPrice to Public plus VAT of FF/VI 184/22 and 92/22 mcg

bUC cost calculated as a weighted average drug cost of all available presentations at Price to Public plus VAT

cCosts annualised at updated to 2018

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Laura Amanda Vallejo-Aparicio
    • 1
    Email author
  • Jesús Molina
    • 2
  • Iñigo Ojanguren
    • 3
    • 4
  • Ana Viejo Casas
    • 5
  • Alicia Huerta
    • 1
  • Henrik Svedsater
    • 6
  1. 1.Market Access, GSK (GlaxoSmithKline)MadridSpain
  2. 2.Centro de Salud FranciaFuenlabradaSpain
  3. 3.Servicio de NeumologíaHospital Universitario Vall d’HebronBarcelonaSpain
  4. 4.Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos III (ISCIII)BarcelonaSpain
  5. 5.Centro de Salud Pisueña CayonCantabriaSpain
  6. 6.Value Evidence and Outcomes, GSKBrentfordUK

Personalised recommendations